Form 4: Cognition Therapeutics CEO Lisa Ricciardi Reports Significant Stock Vesting and Tax Withholding

Cognition Therapeutics CEO Lisa Ricciardi reported the vesting of 75,000 performance stock units and the subsequent disposition of 23,400 shares for tax obligations, increasing her direct beneficial ownership to 938,666 shares.

Summary

• Lisa Ricciardi, CEO and President of Cognition Therapeutics Inc. (CGTX), acquired 75,000 shares of common stock on July 29, 2025, at a price of $0.00 per share.
• These shares were earned upon the vesting of performance stock units (PSUs) granted on February 14, 2024, with 50% of the total PSUs vesting on this date.
• Concurrently, 23,400 shares were disposed of at a price of $0.6702 per share to cover tax withholding obligations related to the PSU vesting.
• Following these transactions, Lisa Ricciardi's direct beneficial ownership stands at 938,666 shares, with an additional 38,851 shares held indirectly by her spouse.

Sentiment

Score: 7

Explanation: The filing indicates the achievement of performance goals leading to PSU vesting, which is a positive sign of management's performance. The subsequent tax withholding is a routine, neutral event. The overall sentiment is positive due to the successful vesting and continued significant insider ownership.

Positives

• Vesting of 75,000 performance stock units indicates the achievement of performance goals set by the company.
• The CEO's continued direct beneficial ownership of 938,666 shares demonstrates significant alignment with shareholder interests.

Negatives

• Disposition of 23,400 shares to cover tax withholding obligations reduces the total number of shares directly held by the CEO, although this is a standard practice.

Future Outlook

NA

Industry Context

This filing reflects standard executive compensation practices within the biotechnology or pharmaceutical industry, where performance-based equity awards like PSUs are common to align executive incentives with company performance.

Comparison to Industry Standards

• The use of Performance Stock Units (PSUs) for executive compensation is a common practice across the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term company performance and shareholder value creation.
• The disposition of shares to cover tax withholding obligations upon equity vesting is a standard and expected procedure for executives receiving equity compensation, consistent with practices observed at comparable companies such as Biogen Inc. (BIIB) or Gilead Sciences, Inc. (GILD) when their executives' restricted stock units (RSUs) or PSUs vest.
• The CEO's significant direct and indirect beneficial ownership post-transaction, totaling 977,517 shares, indicates a strong vested interest in the company's success, which is generally viewed positively by investors and aligns with best practices for executive share retention in the industry.

Stakeholder Impact

• Shareholders: The vesting of PSUs suggests that performance targets have been met, which could be viewed positively as it indicates management's success in achieving company objectives. The CEO's continued significant shareholding aligns her interests with shareholders.
• Employees: While not directly impacted, successful executive compensation programs can signal a healthy company environment.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (PSU vesting and tax withholding) and does not contain new material information that would fundamentally alter the investment thesis for Cognition Therapeutics. The vesting indicates performance goals were met, which is positive, but the transaction itself is expected and does not warrant a change in investment recommendation based solely on this filing. The CEO's continued significant ownership is a positive sign of alignment.

Keywords

Cognition Therapeutics, CGTX, Lisa Ricciardi, SEC Form 4, Insider Trading, Stock Vesting, Performance Stock Units, PSUs, Executive Compensation, Share Ownership, Tax Withholding